This trial will study the effects of brentuximab vedotin when used with CHP to treat PTCL. It will also study any side effects that occur when the two drugs are used together.
1 Primary · 7 Secondary · Reporting Duration: Approximately 3 years
Experimental Treatment
80 Total Participants · 2 Treatment Groups
Primary Treatment: brentuximab vedotin · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: